WO1998048013A1 - Brca2 transcriptional activator domain and uses thereof - Google Patents
Brca2 transcriptional activator domain and uses thereof Download PDFInfo
- Publication number
- WO1998048013A1 WO1998048013A1 PCT/GB1998/001181 GB9801181W WO9848013A1 WO 1998048013 A1 WO1998048013 A1 WO 1998048013A1 GB 9801181 W GB9801181 W GB 9801181W WO 9848013 A1 WO9848013 A1 WO 9848013A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brca2
- fragment
- sequence
- nucleic acid
- variant
- Prior art date
Links
- 101150008921 Brca2 gene Proteins 0.000 title claims abstract description 178
- 108091006106 transcriptional activators Proteins 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 232
- 102000052609 BRCA2 Human genes 0.000 claims abstract description 174
- 108700020462 BRCA2 Proteins 0.000 claims abstract description 174
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 174
- 229920001184 polypeptide Polymers 0.000 claims abstract description 152
- 239000012634 fragment Substances 0.000 claims abstract description 111
- 239000000126 substance Substances 0.000 claims abstract description 67
- 238000003556 assay Methods 0.000 claims abstract description 55
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims abstract description 46
- 238000013518 transcription Methods 0.000 claims abstract description 35
- 230000035897 transcription Effects 0.000 claims abstract description 35
- 230000003213 activating effect Effects 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 130
- 102000039446 nucleic acids Human genes 0.000 claims description 122
- 108020004707 nucleic acids Proteins 0.000 claims description 122
- 238000000034 method Methods 0.000 claims description 96
- 230000027455 binding Effects 0.000 claims description 91
- 238000012360 testing method Methods 0.000 claims description 64
- 150000001413 amino acids Chemical class 0.000 claims description 55
- 230000014509 gene expression Effects 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- 230000004568 DNA-binding Effects 0.000 claims description 29
- 230000003993 interaction Effects 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 108091000080 Phosphotransferase Proteins 0.000 claims description 11
- 102000020233 phosphotransferase Human genes 0.000 claims description 11
- 101000934858 Homo sapiens Breast cancer type 2 susceptibility protein Proteins 0.000 claims description 10
- 102000047599 human BRCA2 Human genes 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000004075 alteration Effects 0.000 claims description 9
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims description 7
- 108010033276 Peptide Fragments Proteins 0.000 claims description 5
- 102000007079 Peptide Fragments Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- 230000004913 activation Effects 0.000 abstract description 40
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 83
- 108090000623 proteins and genes Proteins 0.000 description 68
- 239000000523 sample Substances 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 41
- 230000000694 effects Effects 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 29
- 230000035772 mutation Effects 0.000 description 29
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 23
- 238000012216 screening Methods 0.000 description 23
- 108700028369 Alleles Proteins 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- 108020004705 Codon Proteins 0.000 description 18
- 102100039556 Galectin-4 Human genes 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 239000013615 primer Substances 0.000 description 16
- 230000002103 transcriptional effect Effects 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 13
- 108700008625 Reporter Genes Proteins 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 13
- 230000009870 specific binding Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 108091081021 Sense strand Proteins 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 11
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000002751 oligonucleotide probe Substances 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108700010154 BRCA2 Genes Proteins 0.000 description 7
- 208000033640 Hereditary breast cancer Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003155 DNA primer Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 6
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 102100023132 Transcription factor Jun Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 101100235354 Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440) lexA1 gene Proteins 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 101150047523 lexA gene Proteins 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000010396 two-hybrid screening Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010001515 Galectin 4 Proteins 0.000 description 4
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000003348 filter assay Methods 0.000 description 4
- -1 from genomic sources Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 229910009891 LiAc Inorganic materials 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003160 two-hybrid assay Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000008863 intramolecular interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 238000007420 radioactive assay Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 101100206185 Arabidopsis thaliana TCP18 gene Proteins 0.000 description 1
- 101100206195 Arabidopsis thaliana TCP2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101150007280 LEU2 gene Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108700002667 S cerevisiae GAL4 (1-147) Proteins 0.000 description 1
- 101100004651 Schizosaccharomyces pombe (strain 972 / ATCC 24843) brc1 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 101150109301 lys2 gene Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009598 prenatal testing Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910001426 radium ion Inorganic materials 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention provides polypeptides, nucleic acid encoding the polypeptides, substances which interact
- activator domain severely reduces activation of transcription. Furthermore, molecules (polypeptide domains) which interact with this region of the BRCA2 polypeptide have been identified experimentally and may be used to modulate
- FIG. 1 shows that sequences within exon 3 of BRCA2
- FIG. 2 shows the protein and DNA sequence of residues
- FIG 3 shows the amino acid and DNA sequence of a portion of the protein named "BBPl” (BRCA2 Binding Protein-1) found to interact with the BRCA2 TAD and to modulate its transcriptional activation.
- BBPl BRCA2 Binding Protein-1
- polypeptide which has the amino acid sequence of a fragment of BRCA2 protein and which is able to
- acids less than about 120 amino acids, less than about 100
- amino acids or less than about 70 amino acids.
- polypeptides according to this aspect of the present invention may include or be fused or otherwise operably linked to a DNA binding domain, which may be heterologous or
- BRCA2 foreign to BRCA2 , e.g. being of a polypeptide such as GAL4 , or LexA or any suitable example, of which many are known and
- inhibitory domains within the fusion protein.
- a polypeptide according to the present invention may be any polypeptide according to the present invention.
- Figure 2 or an amino acid sequence which is a fragment, mutant, variant, allele or derivative thereof.
- particular embodiments of the present invention may make individual use of the two fragments of the exon 3 activation
- fragments within the fragment of BRCA2 residues 18-105 may be
- polypeptide may be used to identify regions and/or residues
- polypeptide may include an amino acid sequence which differs
- variants derivatives, alleles, mutants and homologues, e.g.
- amino acid sequence shares homology with amino acid sequence
- sequence or Figure 2 preferably at least about 30%, or 40%, or 50%, or 60%, or 70%, or 75%, or 80%, or 85% homology, or at least about 90% or 95% homology.
- homology at the amino acid level is generally in terms of amino acid similarity or identity. Similarity allows for "conservative variation”, i.e.
- valine leucine or methionine for another, or the
- Similarity may be as defined and determined
- GAP uses the Needleman and unsch
- Homology may be over the full-length of the relevant polypeptide or may more preferably be over a contiguous sequence of about 15, 20, 25, 30, 40, 50 or more amino acids, compared with the relevant wild-type amino acid sequence.
- Preferred polypeptides may include a transcriptional
- activation domain with at least about 50%, 60%, 70%, 80%,
- the present invention extends to
- nucleic acid that hybridizes with any one or more of the
- Suitable conditions include, e.g. for detection
- the residues 18-105 fragment of BRCA2 polypeptide is referred to as the BRCA2 transcription
- TAD activation domain
- PAR primary activating region
- One such embodiment includes the portion from residues 126 to 197, or a fragment, mutant, allele, variant or derivative thereof.
- polypeptide includes or consists essentially of the fragment
- the TAD including the PAR and the AAR is flanked by two "inhibitory regions" which are bound by molecules which inhibit activation of transcription by the TAD, as demonstrated experimentally and described below. The position of the two inhibitory regions is shown
- fragments may be used instead of the wild-type sequence
- a polypeptide which includes IRl and/or IR2 with the BRCA2 TAD may be used in the
- peptides including or
- Inhibitor domains have been shown to be present in a number of transcription factors (references 4, 5, 6 below) .
- throughput screen may be used to find molecules which
- BRCA2 transcriptional activation which may do this by binding the inhibitor domain and preventing an intramolecular interaction.
- 0 may include or consist essentially of the IRl and/or IR2 sequences shown in Figure 2. Where additional amino acids are included, which amino acids may be from BRCA2 (so that the peptide is a larger fragment of BRCA2) or may be heterologous or foreign to BRCA2 , the peptide may be about
- a peptide according to this aspect may be included within a larger fusion
- BRCA2 i.e. heterologous or foreign sequence, such as a
- nucleic acid in an expression system.
- the present invention also provides in
- BBPl BRCA2 Binding Protein 1
- nucleic acid according to the present invention is provided as an isolate, in isolated and/or purified form, or free or substantially free of material with which it is naturally associated, such as free or
- Nucleic acid may be wholly or
- genomic DNA partially synthetic and may include genomic DNA, cDNA or RNA.
- nucleic acid according to the invention includes RNA
- samples of such nucleic acid e.g. from genomic sources, (ii) chemical synthesis, or (iii) preparing cDNA sequences.
- Modifications to the BRCA2 sequences can be made, e.g. using site directed mutagenesis, to lead to the expression of
- sequences can be incorporated in a vector
- the vectors may include other sequences such as promoters or enhancers to control its expression.
- the vectors may include other sequences such as promoters or enhancers to control its expression.
- Polypeptide can then be obtained by
- polypeptide is produced and recovering the polypeptide from
- Prokaryotic and eukaryotic cells are used for this purpose in the art,
- E. coli including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells.
- yeast including strains of E. coli, yeast, and eukaryotic cells such as COS or CHO cells.
- eukaryotic cells such as COS or CHO cells.
- the present invention also encompasses a method of making a polypeptide or peptide (as disclosed) , the method
- polypeptide or peptide generally nucleic acid according to
- Polypeptides and peptides may also be expressed in in vitro systems, such as reticulocyte lysate.
- host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems.
- polypeptide include Chinese hamster ovary cells, HeLa cells,
- E. coli common, preferred bacterial host is E. coli.
- Suitable vectors can be chosen or constructed,
- Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate.
- plasmids viral e.g. 'phage, or phagemid, as appropriate.
- nucleic acid for manipulation of nucleic acid, for example in preparation
- nucleic acid constructs mutagenesis, sequencing,
- the nucleic acid of the invention may be integrated into
- the nucleic acid may be on an extra-chromosomal vector within the cell, or otherwise identifiably
- a still further aspect provides a method which includes introducing the nucleic acid into a host cell.
- the introduction which may (particularly for in vi tro
- transformation may employ any available technique.
- suitable techniques may include calcium
- retrovirus or other virus e.g. vaccinia or, for insect cells, baculovirus.
- retrovirus or other virus e.g. vaccinia or, for insect cells, baculovirus.
- vaccinia e.g. vaccinia
- insect cells e.g. vaccinia
- baculovirus e.g. vaccinia
- suitable techniques for bacterial cells, suitable techniques
- sensitivity genes may be used in identifying clones
- nucleic acid of interest containing nucleic acid of interest, as is well known in the
- the introduction may be followed by causing or allowing
- the encoded polypeptide (or peptide) is produced. If the
- polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the
- a polypeptide or peptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a
- composition which may include one or more additional ingredients
- nucleic acid may take place in vivo by
- a host cell containing nucleic acid according to the
- nucleic acid into the cell or into an ancestor of the cell
- cell or ancestor (which introduction or alteration may take place in vivo or ex vivo) , may be comprised (e.g. in the
- soma within an organism which is an animal, particularly a
- mammal which may be human or non-human, such as rabbit,
- guinea pig, rat, mouse or other rodent cat, dog, pig, sheep, goat, cattle or horse, or which is a bird, such as a chicken.
- _ sequence may allow the organism to be used as a model in
- a polypeptide according to the present invention may be any polypeptide according to the present invention.
- Such molecules may be useful in a therapeutic (possibly including prophylactic) context.
- the present invention relates to screening and assay methods and means, and substances
- the invention includes providing a polypeptide or peptide of
- Binding may be determined by
- Further assays are for substances which interact with or bind the TAD and/or modulate its ability to activate transcription.
- BBPl BRCA2 Binding Protein-1
- Assays of the invention may therefore use the BRCA2 TAD, or
- transcriptional activation may stimulate and/or enhance
- Jnk Jun N-terminal kinase
- phosphorylase removes the phosphate to deactivate the transcriptional activator function.
- a molecule that inhibits or prevents the dephosphorylation may be used to enhance transcriptional activation.
- Such a molecule may include a
- the BRCA2 TAD has significant sequence homology with the TAD of Jun and a kinase is able to bind it.
- a kinase is able to bind it.
- Phosphorylation may be determined for example by
- Such antibodies may be
- Phosphorylation may be determined by immobilisation of BRCA2 or a fragment, mutant, variant or
- a suitable substrate such as a bead or
- Another aspect of the present invention provides an assay (A) which includes :
- polypeptide or peptide and the test substance.
- TAD, IRl and/or IR2 may be isolated and/or purified
- the present invention provides an
- the present invention including a BRCA2 TAD and optionally a
- IRl and/or IR2 and a DNA binding domain capable of binding a
- nucleotide sequence within a promoter and a putative
- polypeptide is capable of binding to activate transcription of a sequence operably linked to the promoter
- a compound which binds IRl and/or IR2 may inhibit transcriptional activation by the polypeptide.
- a molecule which binds IRl and/or IR2 in vivo e.g. a molecule naturally present in a mammalian, e.g. human, tumour
- non-tumour cell e.g. breast tumour
- a breast tumour e.g. breast tumour
- non-tumour cell e.g. breast tumour
- molecule which inhibits transcriptional activation by the BRCA2 TAD obtainable using assay (A) or assay (B) may be isolated and may be manufactured, and may be subsequently used to assay for substances which interfere with its binding _ to IRl and/or IR2 within BRCA2 polypeptide and/or ability to inhibit BRCA2 TAD transcriptional activation.
- Such an assay may include bringing into contact a
- peptide or polypeptide including a IRl or IR2 sequence and a
- binding molecule for the IRl or IR2 sequence (such as obtainable by means of assay (A) or assay (B) ) in the
- test conditions are
- binding molecule such binding occurs, and determining binding between the IRl and/or IR2. This may be followed by
- Fragments may be generated and used in any combination
- fragments may be generated by taking encoding DNA, identifying suitable restriction enzyme recognition sites
- the portion from the DNA.
- the portion may then be operably
- primers Small fragments (up to about 20 or 30 amino acids)
- a polypeptide may be fused to a heterologous DNA binding
- the GAL 4 transcription factor includes two functional domains. These domains are the DNA binding domain (GAL4DBD)
- GAL4TAD GAL4 transcriptional activation domain
- LexA DNA binding domain and the VP60
- the interaction between the polypeptides may be studied in vi tro by labelling one with a
- Suitable detectable labels include 35 S-methionine which may be incorporated into recombinantly produced peptides and
- polypeptides may also be expressed as a fusion protein
- the protein which is immobilized on a solid support may
- a preferred in vi tro interaction may utilise a
- GST glutathione-S-transferase
- This may be immobilized on glutathione agarose beads.
- beads may be rinsed to remove unbound protein and the amount
- An assay according to the present invention may also take the form of an in vivo assay.
- the in vivo assay may be performed in a cell line such as a yeast strain in which the relevant polypeptides or peptides are expressed from one or
- a further assay according to the present invention tests
- BRCA2 TAD activation by BRCA2 TAD, e.g. by inhibiting interaction of
- IRl and/or IR2 with a binding molecule or respective binding
- Such an assay may involve :
- the present invention including a BRCA2 TAD and a IRl and/or
- IR2 and a DNA binding domain capable of binding a nucleotide
- IRl and/or IR2 inhibit (s) transcriptional activation of the
- polypeptide is capable of binding to activate transcription of a sequence operably linked to the promoter when the
- polypeptide is not bound by the IRl and/or IR2 binding
- a reporter gene construct including a promoter which
- Two or more binding sites (for example 3, 4 or 5)
- nucleic acid construct may be present in the nucleic acid construct and this may
- operably linked in the context of a sequence of interest and a promoter means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter.
- DNA operably linked to a promoter is "under transcriptional
- the gene may be transcribed into rnRNA which may be translated into a peptide or polypeptide product which
- reporter gene i.e. a gene
- a reporter gene preferably encodes an enzyme which catalyses a reaction which produces a detectable signal, preferably a visually detectable signal, such as a coloured
- ⁇ -galactosidase activity may be assayed by production of blue colour on substrate, the assay being by
- Fluorescence for example that produced as a result of
- luciferase activity may be quantitated using a
- Radioactive assays may be used, for
- the binding molecule may be labelled directly or indirectly using
- a method of screening for ability of a substance to modulate activity of a promoter may include contacting an expression system, such as a host cell, containing assay
- the presence of the test substance indicates ability of the test substance
- a promoter construct may be introduced into a cell line
- the cell line containing the reporter construct integrated into the genome may be grown and incubated with test
- the cells may be grown in 96
- the cells may then be washed and the reporter
- the substance may be investigated further. Furthermore, it may be manufactured
- compositions such as a medicament, pharmaceutical
- composition or drug may be administered to a subject.
- composition or drug may be administered to a subject.
- concentrations of putative inhibitor compound may be used,
- Compounds which may be used may be natural or synthetic
- putative inhibitor compounds can be derived from the BRCA2
- Peptides can also be generated wholly or partly by
- binding regions determined to provide single chain antibodies and fragments thereof which are responsible for disrupting
- Antibodies may be obtained using techniques which are
- a mammal e.g. mouse, rat, rabbit, horse, goat,
- Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened,
- producing cells from an animal may be accompanied by a step of sacrificing the animal .
- an antibody specific for a protein may be
- the library may be naive, that
- fragments may be one constructed using sequences obtained from an organism which has been exposed to the
- Antibodies according to the present invention may be any suitable antibodies according to the present invention.
- invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic
- Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CHI domains; the Fd fragment consisting of the VH and CHI domains; the Fv fragment consisting of the NL and VH domains of a single arm of an antigen or other binding partner.
- the dAb fragment which consists of a VH domain
- the present invention may be subject to genetic mutation or
- a monoclonal antibody can be any monoclonal antibody.
- Such techniques may involve introducing D ⁇ A encoding the immunoglobulin variable region, or the complementarity determining regions
- binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including
- the invention also provides methods of production of the
- antibodies including growing a cell capable of producing the
- the reactivities of antibodies on a sample e.g. the
- the reporter molecules may be any suitable reporter molecules.
- the reporter molecules may be any suitable reporter molecules.
- reporter molecules may be any linkage of reporter molecules.
- Linkage via a peptide bond may be as
- Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red.
- Suitable chromogenic dyes include diaminobenzidine .
- Other reporters include macromolecular colloidal
- - particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or
- molecules may be enzymes which catalyse reactions that
- properties for example. They may be molecularly excitable,
- Biosensors Biotin/avidin or biotin/streptavidin and
- alkaline phosphatase detection systems may be employed.
- the mode of determining binding is not a feature of the present invention and those skilled in the art are able to
- Antibodies in accordance with the present invention may be used in screening for the presence of a particular polypeptide, for example in a test sample containing cells or
- cell lysate as discussed, such as a BRCA2 polypeptide including a mutation in the TAD, IRl and/or IR2, where such _ mutation is reflected in an alteration in one or more
- Antibodies may also be used in purifying and/or
- an individual may be useful in a therapeutic context (which
- prophylaxis may include prophylaxis
- An antibody may be provided in a kit, which may include instructions for use of the antibody, e.g. in determining the
- One or more other reagents may be included, such as labelling
- Reagents may be provided within containers which protect them from the external environment , such as a sealed vial .
- candidate inhibitor compounds may be based on modelling the 3 -dimensional structure of a polypeptide or
- the invention provides compounds
- the assay of the invention when conducted in vivo,
- composition to a patient, e.g. for anti-tumour or other anti-
- proliferative treatment which may include preventative
- composition including admixing such a
- substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.
- BRCA2 polypeptide TAD IRl or IR2
- binding ligand or ligands for IRl and/or IR2 which interfere with interaction between these polypeptides, and/or transcriptional activation by BRCA2 TAD.
- functional mimetic means a substance which may not contain an active portion of the
- a substance identified using the present invention may be any substance identified using the present invention.
- Non-peptide small
- peptides are not well suited as active agents for oral compositions as they tend to be 0 quickly degraded by proteases in the alimentary canal.
- Mimetic design, synthesis and testing may be used to avoid randomly screening large number of molecules for a target property. There are several steps commonly taken in the design of
- a range of sources e.g. spectroscopic techniques, X-ray
- mapping (which models the charge and/or volume of a
- a template molecule is then selected onto which chemical groups which mimic the pharmacophore can be grafted.
- the mimetic is easy to synthesise, is likely to be pharmacologically acceptable
- administration is preferably in a "prophylactically effective
- a composition may be administered alone or in
- compositions according to the present invention are provided.
- inventions and for use in accordance with the present invention, may include, in addition to active ingredient, a
- injection e.g. cutaneous, subcutaneous or intravenous.
- compositions for oral administration may include
- a tablet may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid
- Physiological saline solution dextrose or other saccharide solution or glycols such as ethylene glycol , propylene glycol or polyethylene glycol may be included.
- isotonic vehicles such as Sodium Chloride Injection
- peptide or other substance as disclosed herein may be provided in a kit, e.g. sealed in a suitable container which
- kit may include instructions for use.
- IR2 may be used in diagnostic and prognostic screening.
- Oligonucleotide probes or primers as well as the full- length BRCA2 TAD (optionally including IRl and/or IR2)
- nucleic acid useful in screening a test sample containing nucleic acid for
- the probes include cancers, the probes
- hybridisation can be controlled to minimise non-specific
- binding and preferably stringent to moderately stringent
- Nucleic acid isolated and/or purified from one or more cells e.g. human
- a nucleic acid library derived from nucleic acid isolated and/or purified from cells e.g. a cDNA library derived from mRNA isolated from the cells
- PCR polymerase chain reaction
- a method may include hybridisation of one or more (e.g.
- nucleic acid is double-stranded DNA, hybridisation will be
- the hybridisation may be as part of a PCR
- PCR An example procedure would be a combination of PCR and
- binding of a probe to target nucleic acid may be any suitable nucleic acid (e.g. DNA).
- target nucleic acid e.g. DNA
- probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe
- Probing may employ the standard Southern blotting technique . For instance DNA may be extracted from cells and
- fragments may then be separated by electrophoresis on an
- Labelled probe may be hybridised to
- RNA preparations from cells may be prepared from RNA preparations from cells.
- the target sequence is known to allow suitable forward and reverse oligonucleotide primers to be designed to be identical or similar to the polynucleotide sequence that is
- PCR includes steps of denaturation of template nucleic acid (if double-stranded) ,
- the nucleic acid probed or used as template in the amplification reaction may be genomic DNA, cDNA or RNA.
- PCR can be used to amplify specific sequences from genomic DNA, specific RNA
- oligonucleotide probes or primers may be designed, taking
- nucleic acid is derived.
- nucleic acid amplification may have about 10 or fewer codons
- primers for use processes such as PCR.
- a further aspect of the present invention provides an oligonucleotide or polynucleotide fragment of the nucleotide sequence shown for the BRCA2 TAD, IRl and IR2 regions in
- nucleotides but preferably without abolition of ability to hybridise selectively with nucleic acid with the sequence
- oligonucleotides In some preferred embodiments, oligonucleotides
- disorder of cell proliferation are at least about 10
- nucleotides in length more preferably at least about 15 nucleotides in length, more preferably at least about 20
- Fragments and other oligonucleotides may be used as primers or probes as discussed but may also be generated (e.g. by
- PCR in methods concerned with determining the presence in a test sample of a sequence indicative of susceptibility to cancer or other disorder of cell -cycle regulation.
- susceptibility in the coding sequence shown in Figure 2 may be about 20 nucleotides in length, or may include a
- oligonucleotide sequence may be designed so that it
- Figure 2 thus include :
- oligonucleotides will anneal without mismatch to
- TAT at codon 42 is mutated to TGT.
- wild-type sequence with mismatch include 5 ' -TGTAATTCTGAACCTGCAGA-3 '
- oligonucleotides may be employed for any mutation or other sequence alteration within a BRCA2 fragment according to the present invention.
- fragments include: 5'-ATGCCTATTGGATCCAAAGA-3 '
- oligonucleotides may be used in various ways. These and other oligonucleotides may be used in various ways.
- the methods may be used to detect alleles
- cancer or other proliferative disorder in the future, e.g.
- the methods divide into those screening for the
- nucleic acid sequences or polypeptide are suspected of contain the nucleic acid sequences or polypeptide.
- biological samples include blood,
- Exemplary approaches for detecting nucleic acid or polypeptides include:
- IRl and/or IR2 IRl and/or IR2 ) , and/or is mutated in such a region; or,
- nucleic acid sequence either a normal sequence or a nucleic acid sequence
- binding member including nucleic acid hybridisable with the
- a "specific binding pair” includes a specific binding
- binding partner (bm) and a binding partner (bp) which have a particular specificity for each other and which in normal
- binding member and the binding partner include a part of a
- the specific binding pair are nucleic acid sequences, they will be of a length to hybridise to each other under the conditions of the assay, preferably greater than 10 nucleotides long, more preferably greater than 15 or 20 nucleotides long. In most embodiments for screening for susceptibility
- analyte as compared to other sequences present in the sample .
- This initial step may be avoided by using highly sensitive array techniques that are becoming increasingly important in
- the gene may be for diagnosing cancer of a patient with the disease as being associated with the gene.
- a variant form of the gene may contain one or more
- nucleic acid level are not necessarily reflected by a
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002288335A CA2288335A1 (en) | 1997-04-23 | 1998-04-23 | Brca2 transcriptional activator domain and uses thereof |
EP98917445A EP0977847A1 (en) | 1997-04-23 | 1998-04-23 | Brca2 transcriptional activator domain and uses thereof |
AU70674/98A AU7067498A (en) | 1997-04-23 | 1998-04-23 | Brca2 transcriptional activator domain and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9708221.8 | 1997-04-23 | ||
GBGB9708221.8A GB9708221D0 (en) | 1997-04-23 | 1997-04-23 | Substances and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998048013A1 true WO1998048013A1 (en) | 1998-10-29 |
Family
ID=10811226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/001181 WO1998048013A1 (en) | 1997-04-23 | 1998-04-23 | Brca2 transcriptional activator domain and uses thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0977847A1 (en) |
AU (1) | AU7067498A (en) |
CA (1) | CA2288335A1 (en) |
GB (1) | GB9708221D0 (en) |
WO (1) | WO1998048013A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022689A1 (en) * | 1995-12-18 | 1997-06-26 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
-
1997
- 1997-04-23 GB GBGB9708221.8A patent/GB9708221D0/en active Pending
-
1998
- 1998-04-23 CA CA002288335A patent/CA2288335A1/en not_active Abandoned
- 1998-04-23 WO PCT/GB1998/001181 patent/WO1998048013A1/en not_active Application Discontinuation
- 1998-04-23 AU AU70674/98A patent/AU7067498A/en not_active Abandoned
- 1998-04-23 EP EP98917445A patent/EP0977847A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022689A1 (en) * | 1995-12-18 | 1997-06-26 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
Non-Patent Citations (4)
Title |
---|
DATABASE GENBANK 26 May 1996 (1996-05-26), HILLIER L. ET AL.: "EST; H. sapiens clone 324322", XP002076944 * |
MILNER J. ET AL.: "Transcriptional activation functoions in BRCA2.", NATURE, vol. 386, 24 April 1997 (1997-04-24), pages 772 - 773, XP002076943 * |
SHARAN S. & BRADLEY A.: "Murine Brca2: sequence, map position and expression pattern", GENOMICS, vol. 40, no. 2, 1 March 1997 (1997-03-01), pages 234 - 241, XP002076941 * |
TAVTIGIAN S.V. ET AL.: "The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds", NATURE GENETICS, vol. 12, no. 3, March 1996 (1996-03-01), pages 333 - 337, XP002076942 * |
Also Published As
Publication number | Publication date |
---|---|
EP0977847A1 (en) | 2000-02-09 |
GB9708221D0 (en) | 1997-06-11 |
CA2288335A1 (en) | 1998-10-29 |
AU7067498A (en) | 1998-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5691147A (en) | CDK4 binding assay | |
AU687764B2 (en) | Cyclin complex rearrangement and uses related thereto | |
US5889169A (en) | Cell cycle regulatory protein p16 gene | |
US6753158B1 (en) | Assays, agents, therapy and diagnosis relating to modulation of cellular DNA repair activity | |
US20040072268A1 (en) | Methods for regulating BRCA1-BRCA2-containing complex activity | |
WO1998048013A1 (en) | Brca2 transcriptional activator domain and uses thereof | |
CA2262479A1 (en) | Brca1 associated protein (bap-1) and uses therefor | |
US6890709B1 (en) | Assays, methods and means for modulating e2f activity | |
WO1997041433A1 (en) | METHOD AND MEANS FOR DISRUPTION OF p53 AND RB INTERACTION | |
US7348407B2 (en) | Stress-responsive activator of p300 (strap) protein | |
EP1105738B1 (en) | Assays for modulating nuclear localisation | |
US6331390B1 (en) | Cell-cycle regulatory proteins, and uses related thereto | |
WO1997035975A1 (en) | E2f-like transcription repressor and dna encoding it | |
JP2002508180A (en) | Human RAD1 nucleic acids, polypeptides, assays, therapeutic methods and means | |
WO2001081587A1 (en) | Acetyltransferase and uses thereof | |
EP1222264A1 (en) | Human sit4 associated proteins like (sapl) proteins and encoding genes; uses thereof | |
JP2000512133A (en) | Identification of altered genes in multiple myeloma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2288335 Country of ref document: CA Ref country code: CA Ref document number: 2288335 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 70674/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998917445 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09402610 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998917445 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998545300 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998917445 Country of ref document: EP |